The CDC estimates 93 m adults in the US are at high risk for serious vision loss.
More than 90% of vision loss caused by chronic conditions, including impairment caused by diabetic retinopathy, macular degeneration, and glaucoma, is preventable.
Yet these conditions remain leading causes of blindness--largely due to poor adherence to recommended care.
Lumata Health currently serves thousands of patients suffering from vision-threatening chronic eye conditions through partnerships with ophthalmology clinics and health systems.
Data shows patients supported by Lumata Health's intelligent eye care management platform, which incorporates clinical and psychosocial elements to empower patients to manage their chronic condition throughout their care journey, miss an average of 30% fewer appointments.
Patients are connected with an experienced, certified eye care coordinator that works with them to ensure adherence to their doctor's care plan through ongoing education and addressing barriers to care.
Hadley provides personalized learning opportunities that empower adults with vision loss or blindness to thrive at home, at work, and in their communities.
The Hadley team draws on expertise in vision rehabilitation, digital technology, instructional design, and an advisory panel of more than 1,000 people with vision impairment to deliver a user-centered approach to content creation, resulting in 98% user satisfaction rating across Hadley's library of workshops.
Since relaunching in July 2020, more than 54,000 people have signed up with Hadley, registering nearly 200,000 workshop interactions across all 50 states and 100 countries.
Patients in Lumata's network will be given free access to Hadley resources and assisted through the sign-up process by a Lumata representative to take advantage of all relevant tools and tutorials.
All individuals experiencing vision impairment can access Hadley's services for free by signing up here.
Follow Lumata Health's social channels (Twitter, LinkedIn and Facebook) and Hadley's social channels (Twitter, LinkedIn and Facebook) for the latest news and information.
Lumata Health is a technology-driven healthcare startup company focused on preventing blindness from chronic eye conditions, managing thousands of people at risk of vision loss across the United States.
Founded in 2017 by an ophthalmologist and retina specialist in practice for over 30 years, Stephen R. Fransen, MD, and supported by more than 30 industry luminaries and influencers on its advisory board, Lumata Health aims to stop preventable blindness with a human-led, intelligent care coordination and management platform that's almost always free to the patient.
The company partners with physicians, payers and health systems to offer turnkey care management services provided by eye care experts who are supported by technology and data science.
Lumata Health's programs improve clinical outcomes, patient satisfaction, and clinic staff efficiency by providing between-visit patient assistance and care coordination for patients with chronic eye diseases such as diabetic retinopathy, macular degeneration, glaucoma, and dry eye.
Founded in 1920 by William Hadley, an educator who lost his eyesight later in life, Hadley offers practical help, connection and support free of charge to anyone with a visual impairment, their families and professionals supporting them.
A 501(c) (3) non-profit organization, Hadley is a partner of the National Eye Institute and the National Eye Health Education Program.
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
GSK wins European Commission approval for Shingrix prefilled syringe
Abbott launches Libre Assist for in-the-moment food decisions
RedHill advances RHB-102 across GI indications
FDA grants priority review for Sanofi's Tzield in young children with stage 2 type 1 diabetes
Samsung Bioepis begins direct commercialisation of BYOOVIZ in Europe
Diamyd Medical agrees accelerated efficacy readout in ongoing Phase 3 type 1 diabetes trial
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study
Qlife's Egoo Health platform selected for major AI-driven diabetes and MASLD project in China
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Gan & Lee Pharmaceuticals launches third phase 3 trial of once-monthly bofanglutide
Novo Nordisk reports strong phase 2 results for amycretin in type 2 diabetes
Innovent Biologics reports primary and all key secondary endpoints met in mazdutide Phase 3 trial
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Adocia files patent for long-acting peptide platform AdoXLong and updates on BioChaperone studies